US 11,311,497 B2Granted

Method for screening for diabetes mellitus therapeutic agents

AssigneeUniversity—Industry Corporation Group of Kyung Hee University

InventorHyeung Jin Jang

Life of this patent

Estimating the term…

Loading patent…

Abstract

Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, and a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering to the individual a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition. Also provided is a screening method for an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (GLP-1) secreted from the cell; and determining that the test material, when the test material promotes expression of GLP-1, as a candidate material for an antidiabetic agent. In addition, a quasi-drug composition and a cosmetic composition including geraniol for uses are provided.

Claims6

Dependent claims

A method of screening a test material to determine if the test material is a candidate for an antidiabetic agent for administration by inhalation, the method comprising:

(a) contacting
(i) an NCI-H716 cell, or a culture thereof, expressing human olfactory receptors OR1A1 and OR with the test material;
and
(ii) an NCI-H716 cell, or a culture thereof, for which the OR1A1 and/or OR1G1 expression has been knocked down with the test material;
(b) measuring an expression level of glucagon-like peptide-1 (GLP-1) secreted from the NCI-H716 cell, or the culture thereof, of step (a)(i) expressing human olfactory receptors OR1A1 and OR1G1;
(c) measuring an expression level of glucagon-like peptide-1 (GLP-1) secreted from the NCI-H716 cell, or the culture thereof, of step (a)(ii) for which the OR1A1 and/or OR1G1 expression has been knocked down;
and
(d) if the expression level of GLP-1 measured in the step (b) increases compared with before contacting with the test material, and
the expression level of GLP-1 measured in the step (c) does not increase compared with before contacting with the test material,
determining that the test material is a candidate material for an antidiabetic agent for administration by inhalation.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/657,192Filed 18 Oct 2019 · division
Priority: KR 10-2013-00915961 Aug 2013
Published: US 2021/0069123 A111 Mar 2021
Granted: 26 Apr 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/045
Medicinal preparations containing organic active ingredients: hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives
A61K 9/0043
Galenical forms characterised by the site of application: nose
A61P 3/08
Drugs for disorders of the metabolism: for glucose homeostasis

Family

PCT/KR2014/007141Parent of this division · filed 1 Aug 2014
US 2021/0069123 A1Pre-grant publication · published 11 Mar 2021
Application14/908,210Parent of this division
US 10,493,042 B2Parent of this division
US 2016/0175263 A1Published application
US 11,311,497 B2This patent

From the US filing history. Foreign family members aren’t listed.